Press release
Asia Pacific Fabry Disease Treatment Market Size Projected to Reach USD 1,088.17 Million by 2034 | CAGR: 7.3%
Asia Pacific Fabry Disease Treatment Market
The Asia Pacific Fabry disease treatment market report by Polaris Market Research offers an in-depth comprehension of the rapidly evolving sector. It provides a comprehensive analysis of all key market aspects, including market share, size, trends, and recent developments. In addition, an analysis of the key segments, top regions, and competitive landscape has been provided.
The report examines the market to register a CAGR of 7.3% during 2025-2034. The market was valued at USD 538.75 million in 2024 and is projected to grow to USD 1,088.17 million by 2034.
Market Introduction
Fabry disease treatment involves a combination of targeted therapies and supportive care aimed at reducing the buildup of harmful substances in the body, managing symptoms, and preventing complications. The disease is caused by a deficiency or malfunction of the enzyme alpha-galactosidase A, leading to the accumulation of a fatty substance called globotriaosylceramide (GL-3) in various tissues. The most established treatment is enzyme replacement therapy (ERT), which involves regular intravenous infusions of synthetic alpha-galactosidase A to help reduce GL-3 accumulation. Another approach is chaperone therapy, such as migalastat, which works by stabilizing the patient's faulty enzyme. In addition to these targeted therapies, patients often require supportive treatments like pain management, dialysis for kidney failure, medications for heart conditions, and therapies for stroke prevention.
Get Exclusive Sample Pages of This Report:
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-fabry-disease-treatment-market/request-for-sample
Market Growth Drivers
Increasing Pharmaceutical R&D Investments: The rising pharmaceutical R&D investments across Asia Pacific are playing a pivotal role in fueling the development of advanced therapies for Fabry disease. Global and local biopharmaceutical companies are expanding their clinical trial networks. They are collaborating with regional research institutions to bring innovative treatments to the market, thereby driving the development of the Asia Pacific Fabry disease treatment market.
Expansion of Medical Tourism: The growing expansion of medical tourism across Asia Pacific is having a positive impact on the market development. Countries like Thailand and India have emerged as preferred destinations for patients seeking rare disease diagnostics, owing to their cost-effective healthcare services and specialized care.
Market Key Players
The Asia Pacific Fabry disease treatment market has the presence of both established players and new entrants. A few of the leading market participants include:
• Chiesi Farmaceutici S.p.A.
• JCR Pharmaceuticals Co., Ltd.
• Protalix BioTherapeutics Inc.
• Sanofi
• Takeda Pharmaceutical
• Amicus Therapeutics, Inc.
• Idorsia Pharmaceuticals Ltd.
• Idorsia Pharmaceuticals Ltd.
• ISU ABXIS Co., Ltd.
• Sangamo Therapeutics, Inc.
Inquire more about this Report Before Purchase:
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-fabry-disease-treatment-market/inquire-before-buying
Asia Pacific Fabry Disease Treatment Market Report Highlights
o By route of administration, in 2024, the intravenous route segment accounted for the largest share. The dominance of this segment is attributed to the established use of enzyme replacement therapy (ERT), which is typically administered intravenously.
o Based on therapy, in 2024, the enzyme replacement therapy (ERT) segment accounted for the largest share. This dominance is largely attributed to the extensive clinical evidence supporting ERT in managing both classic and atypical Fabry manifestations.
o The China Fabry disease treatment market accounted for the largest share. This growth is driven by rising awareness among healthcare professionals and patients, improved diagnostic capabilities, and an increasing number of patients being identified and treated.
Market Segmentation
By Route of Administration Outlook (Revenue, USD Million, 2020-2034)
• Intravenous Route
• Oral Route
By Therapy Outlook (Revenue, USD Million, 2020-2034)
• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Others
By Distribution Channel Outlook (Revenue, USD Million, 2020-2034)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Explore The Complete Report:
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-fabry-disease-treatment-market
Country-Wise Insights
The Fabry disease treatment market in China was valued at approximately USD 230 million in 2024. The growing awareness among patients and healthcare professionals is largely fueling market growth in China. Additionally, enhanced diagnostic capabilities and increasing government support are driving market growth in the country.
The market for Fabry disease treatment in India is anticipated to register a CAGR of 7.6% during the projection period. Rising healthcare investments and growing adoption of advanced diagnostic technologies drive this market growth. Enhanced public-private healthcare partnerships are improving access to specialized services, further supporting market development.
By Country Outlook (Revenue, USD Million, 2020-2034)
• China
• Japan
• India
• South Korea
• Taiwan
• Indonesia
• Malaysia
• Pakistan
• Rest of Asia Pacific
More Trending Reports by Polaris Market Research:
Latin America Fabry Disease Treatment Market:
https://www.polarismarketresearch.com/industry-analysis/latin-america-fabry-disease-treatment-market
MENA Fabry Disease Treatment Market:
https://www.polarismarketresearch.com/industry-analysis/middle-east-north-africa-mena-fabry-disease-treatment-market
LATAM Gaucher Disease Treatment Market:
https://www.polarismarketresearch.com/industry-analysis/latin-america-gaucher-disease-treatment-market
Digital Health For Obesity Market:
https://www.polarismarketresearch.com/industry-analysis/digital-health-for-obesity-market
Chatbot-Based Mental Health Apps Market:
https://www.polarismarketresearch.com/industry-analysis/chatbot-based-mental-health-apps-market
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Asia Pacific Fabry Disease Treatment Market Size Projected to Reach USD 1,088.17 Million by 2034 | CAGR: 7.3% here
News-ID: 4087619 • Views: …
More Releases from Polaris Market Research & Consulting
Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of …
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. It…
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 …
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 3.82 billion in 2024 and is expected to…
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin …
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billion…
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 …
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 31.67 billion in 2024 and is expected to reach…
More Releases for Fabry
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease Market Pipeline 2019 Analysis and Developmental Stages
"Fabry Disease - Pipeline Insight, 2019” report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
